Skip to main content

Market Overview

Biogen's Q2 Numbers, Outlook Exceed Street Expectations

Share:

Biogen Inc (NASDAQ: BIIB) reported 13 percent year-over-year increase in net income for the second quarter driven by 12 percent growth in total revenue. Its adjusted earnings, which witnessed 23 percent year-over-year growth, provided a positive surprise of 11.6 percent. The company also provided an upbeat forecast for the full year apart from authorizing a fresh share repurchase program.

The company reported net income attributable to its shareholders of $1.0 billion or $4.79 a share. On an adjusted basis, it would have earned $1.1 billion or $5.21 a share in the second quarter. This was $0.54 a share higher than the Street expectations of $4.67 a share. While adjusted profit advanced 15 percent, adjusted EPS grew 23 percent on a YOY basis.

Biogen said its total revenue grew 12 percent to $2.9 billion driven by global increase in its multiple sclerosis and hemophilia businesses. This exceeded analysts' predictions of $2.79 billion.

CEO George Scangos commented, "Revenue strength coupled with thoughtful management of expenses helped drive healthy earnings growth for the quarter. As a result, we have raised our financial guidance for the full year. Our Board has also authorized a $5 billion share repurchase program. We believe this allows us to return capital to shareholders, while leaving ample room for strategic flexibility."

Going forward, Biogen expects adjusted earnings to be $19.70-$20.00 a share for the full year. On a GAAP basis, the company sees EPS between $18.10 and $18.40 on revenue of $11.2-$11.4 billion. Analysts are looking for earnings of $18.96 a share and $11.28 billion for the full year.

In pre-market on Thursday, the stock traded 5.77 percent higher.

 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Earnings News Guidance General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com